Essex Bio-Technology (HKSE:01061) Margin of Safety % (DCF Dividends Based) : 67.75% (As of May. 17, 2025)

View and export this data going back to 2001. Start your Free Trial

What is Essex Bio-Technology Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

As of today (2025-05-17), Essex Bio-Technology's Predictability Rank is 2.5-Stars. Essex Bio-Technology's intrinsic value calculated from the Discounted Dividend model is HK$10.75 and current share price is HK$4.36. Consequently,

Essex Bio-Technology's Margin of Safety % (DCF Dividends Based) using Discounted Dividend model is 67.75%.

Competitive Comparison of Essex Bio-Technology's Margin of Safety % (DCF Dividends Based)

For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Essex Bio-Technology's Margin of Safety % (DCF Dividends Based) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Essex Bio-Technology's Margin of Safety % (DCF Dividends Based) falls into.

Save Embed

;

Save Embed

;

Essex Bio-Technology Margin of Safety % (DCF Dividends Based) Calculation

Essex Bio-Technology's Margin of Safety % (DCF Dividends Based) for today is calculated as

Margin of Safety % (DCF Dividends Based)	=	(Intrinsic Value: DCF (Dividends Based)	-	Current Price)	/	Intrinsic Value: DCF (Dividends Based)
	=	(13.52	-	4.36)	/	13.52
	=	67.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Dividend model with default parameters.

Essex Bio-Technology Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Essex Bio-Technology's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Essex Bio-Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Essex Bio-Technology Ltd (HKSE:01061) » Definitions » Margin of Safety % (DCF Dividends Based)

Traded in Other Exchanges

N/A

Address

No. 88, Keji 6th Road, Hi-Tech Zone, Guangdong, Zhuhai, CHN

Website

http://www.essexbio.com

Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel and mouth wash. The majority of the groups revenue comes from PRC.

Executives

Lauw Hui Kian
Ngiam Mia Je Patrick
Ngiam Mia Kiat Benjamin	2101 Beneficial owner

Essex Bio-Technology Headlines

No Headlines